Abstract:Two new Schiff bases and their Pt complexes were synthesized and their structures were elucidated by spectroscopic methods. The ability of the compounds to inhibit Aβ1–42 aggregation in the human neuroblastoma cell line (SH‐SY5Y) was determined. The synthesized complex II was found to be active in inhibiting Aβ1–42 aggregation. For synthesizing metal–organic molecules with pro‐drug properties to prevent the accumulation of amyloid beta (Aβ1–42), which is a feature of neurodegenerative Alzheimer's disease, two new Schiff bases with imine/amine donors 2‐([3,3‐diphenylalidene]amino)‐N,N‐dimethylethane‐1‐amine and N,N‐dimethyl‐2‐([quinolin‐4‐ylmethylene]amino)ethane‐1‐amine, as well as their novel Pt (II) complexes (I and II), were synthesized and characterized via Fourier transform infrared spectroscopy, 1H‐ and 13C‐nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and elemental analyses. The spectroscopic data has shown that the ligands are coordinated to the central atom in a chelating manner. Furthermore, the interaction between these complexes and Aβ1–42 was investigated using the electrochemical methods, square wave voltammetry and pencil graphite electrode, while monitoring the changes in the oxidation signal of the Try residue in Aβ1–42. The ability of the compounds to inhibit Aβ1–42 aggregation was investigated using the human neuroblastoma cell line (SH‐SY5Y). Complex II could actively inhibit the aggregation of Aβ1–42 at a molar ratio of 1.0/1.0, and its Aβ1–42 aggregation kinetics were fluorometrically determined using thioflavin T. These results were supported by scanning electron microscopy and transmission electron microscopy analyses. Moreover, the interaction of complex II with Aβ1–16 was investigated via 1H‐NMR spectroscopy. As a result, it was observed that complex II was effective in inhibiting the aggregation of Aβ1–42 at a molar ratio of 1.0/1.0. This result shows that studies can be conducted on the effects of Schiff base‐Pt complexes as potential pro‐drugs on Alzheimer's disease.

Identification of [ptcl2(phen)] Binding Modes in Amyloid‐β Peptide and the Mechanism of Aggregation Inhibition

PtCl2(phen) disrupts the metal ions binding to amyloid-β peptide.

Inhibitory Action of Macrocyclic Platiniferous Chelators on Metal-Induced Aβ Aggregation

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Organoplatinum‐Substituted Polyoxometalate Inhibits Β‐amyloid Aggregation for Alzheimer's Therapy

A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu<SUP>2+</SUP>-Mediated A Aggregation

Characterization of Copper Binding to the Peptide Amyloid-Beta(1-16) Associated with Alzheimer'S Disease

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Molecular Modeling of the Inhibitory Mechanism of Copper(ii) on Aggregation of Amyloid Β-Peptide

Regulation of Aggregation Behavior and Neurotoxicity of Prion Neuropeptides by Platinum Complexes.

Molecular Modeling on Zn(II) Binding Modes of Alzheimer's Amyloid Β-Peptide in Insoluble Aggregates and Soluble Complexes

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar-Affinity Copper Binding Site on Amyloid β1-42

A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated Aβ Aggregation

Aβ interacts with both the iron center and the porphyrin ring of heme: mechanism of heme's action on Aβ aggregation and disaggregation.

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

Aggregation Pathways Of The Amyloid Beta(1-42) Peptide Depend On Its Colloidal Stability And Ordered Beta-Sheet Stacking

Protein Interactions Between the C-terminus of Aβ-peptide and Phospholipase A2--a Structure Biology Based Approach to Identify Novel Alzheimer's Therapeutics.

Detection and disaggregation of amyloid fibrils by luminescent amphiphilic platinum(II) complexes

Molecular Modeling of Zinc and Copper Binding with Alzheimer’s Amyloid Β-Peptide

Coordination of Platinum to Α‐synuclein Inhibits Filamentous Aggregation in Solution